Evidence map›Paper›PMID 35865516›Full record

ArticleFrontiers in immunology2022

gC1qR/C1qBP/HABP-1: Structural Analysis of the Trimeric Core Region, Interactions With a Novel Panel of Monoclonal Antibodies, and Their Influence on Binding to FXII.

Ying Zhang, Alexander J Vontz, Ethan M Kallenberger, Xin Xu, Nicoleta T Ploscariu, Kasra X Ramyar, Brandon L Garcia, Berhane Ghebrehiwet, Brian V Geisbrecht

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Monocyte Production of C1q Potentiates CD8American journal of respiratory cell and molecular biology · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ying ZhangDepartment of Biochemistry & Molecular Biophysics, Kansas State University, Manhattan, KS, United States.
Alexander J VontzDepartment of Biochemistry & Molecular Biophysics, Kansas State University, Manhattan, KS, United States.
Ethan M KallenbergerDepartment of Biochemistry & Molecular Biophysics, Kansas State University, Manhattan, KS, United States.
Xin XuDepartment of Biochemistry & Molecular Biophysics, Kansas State University, Manhattan, KS, United States.
Nicoleta T PloscariuDepartment of Biochemistry & Molecular Biophysics, Kansas State University, Manhattan, KS, United States.
Kasra X RamyarDepartment of Biochemistry & Molecular Biophysics, Kansas State University, Manhattan, KS, United States.
Brandon L GarciaDepartment of Biochemistry & Molecular Biophysics, Kansas State University, Manhattan, KS, United States.
Berhane GhebrehiwetDepartment of Medicine, Stony Brook University, Stony Brook, NY, United States.
Brian V GeisbrechtDepartment of Biochemistry & Molecular Biophysics, Kansas State University, Manhattan, KS, United States.
Kansas State University · USStony Brook University · US

Funding

Structure/Function Studies of Enzyme Inhibitors and their Roles in Innate Immune EvasionR35GM140852 · NIGMS · KANSAS STATE UNIVERSITY · PI Brian V Geisbrecht · 2021 to 2026
$2.3M
gC1qR as a therapeutic target for angioedema.R56AI122376 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI GHEBREHIWET, BERHANE · 2018 to 2018
$477k
NIAID NIH HHS R56 AI122376NIGMS NIH HHS R35 GM140852
6 · The paper itself

Abstract

The protein gC1qR/C1qBP/HABP-1 plays an essential role in mitochondrial biogenesis, but becomes localized at the cellular surface in numerous pathophysiological states. When this occurs on endothelial cells, surface-exposed gC1qR activates the classical pathway of complement. It also promotes assembly of a multi-protein complex comprised of coagulation factor XII (FXII), pre-kallikrein (PK), and high-molecular weight kininogen (HMWK) that activates the contact system and the kinin-generating system. Since surface-exposed gC1qR triggers intravascular inflammatory pathways, there is interest in identifying molecules that block gC1qR function. Here we further that objective by reporting the outcome of a structure/function investigation of gC1qR, its interactions with FXII, and the impact of a panel of monoclonal anti-gC1qR antibodies on FXII binding to gC1qR. Although deletion mutants have been used extensively to assess gC1qR function, none of these proteins have been characterized structurally. To that end, we determined a 2.2 Å resolution crystal structure of a gC1qR mutant lacking both of its acidic loops, but which retained nanomolar-affinity binding to FXII and FXIIa. This structure revealed that the trimeric gC1qR assembly was maintained despite loss of roughly thirty residues. Characterization of a novel panel of anti-gC1qR monoclonal antibodies identified several with biochemical properties distinct from previously described antibodies, as well as one which bound to the first acidic loop of gC1qR. Intriguingly, we found that each of these antibodies could partly inhibit binding of FXII and FXIIa to gC1qR. Based on these results and previously published studies, we offer new perspectives for developing gC1qR inhibitors.

Indexed as

Antibodies, MonoclonalFactor XIICell MembraneEndothelial CellsKininogen, High-Molecular-WeightAntibodies, MonoclonalFactor XIIKininogen, High-Molecular-WeightFXIIgC1qR/C1qBP/HABP-1inhibitorsmonoclonal antibodiesprotein-protein interactions

Identifiers

PMID35865516
PMCPMC9294231
OpenAlexW4283821584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.